4.6 Article

Monocytes from Depressed Patients Display an Altered Pattern of Response to Endotoxin Challenge

Journal

PLOS ONE
Volume 8, Issue 1, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0052585

Keywords

-

Ask authors/readers for more resources

It is now well established that major depression is accompanied and characterized by altered responses of the immune-inflammatory system. In this study we investigated the pro-inflammatory activation of monocytes isolated from depressed patients as a parameter not influenced by such confounds as the time of day, the nutritional and exercise status or the age and gender of patients. Monocytes from depressed patients and from healthy controls were isolated in vitro; after 24-h incubation under basal conditions, cells were exposed for 24-h to 100 ng/ml of endotoxin (bacterial lipopolysaccharide, LPS). We found that monocytes from drug-free depressed patients and controls release the same amounts of prostaglandin E2 (PGE2) under basal conditions, whereas monocytes from patients are dramatically less reactive to LPS (8.62-fold increase vs previous 24 hrs) compared to healthy controls (123.3-fold increase vs previous 24 hrs). Such blunted prostanoid production was paralleled by a reduction in COX-2 gene expression, whereas other pro-inflammatory mediators, namely interleukin-1 beta (IL-1 beta) and -6 (IL-6) showed a trend to increased gene expression. The above changes were not associated to increased levels of circulating glucocorticoids. After 8 months of antidepressive drug treatment, the increase in PGE2 production after the endotoxin challenge was partially restored, whereas the increase in IL-1 beta and -6 levels observed at baseline was completely abolished. In conclusion, our findings show that the reactivity of monocytes from depressed patients might be considered as a marker of the immune-inflammatory disorders associated to depression, although the lack of paired healthy controls at follow-up does not allow to conclude that monocyte reactivity to endotoxin is also a marker of treatment outcome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Obstetrics & Gynecology

Does mild intrahepatic cholestasis of pregnancy require an aggressive management? Evidence from a prospective observational study focused on adverse perinatal outcomes and pathological placental findings

Stefania Triunfo, Marta Tomaselli, Maria Immacolata Ferraro, Elisabetta Latartara, Giulia Maria Sassara, Cinzia Carrozza

Summary: This study aimed to compare the effects of one-drug therapy (UDCA) and combined therapy (UDCA plus SAMe) on pregnancies complicated by mICP. The results showed no significant differences in adverse perinatal outcomes and placental histopathology between the two treatment methods. Further research and data sharing may lead to changes in the therapeutic plan.

JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE (2022)

Review Pharmacology & Pharmacy

Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature

Cinzia Dello Russo, Kathryn Anne Scott, Munir Pirmohamed

Summary: Dimethyl fumarate (DMF) is a first line medication for multiple sclerosis, but concerns have been raised regarding its adverse effects such as lymphopenia. The molecular mechanisms underlying these effects are not well understood, and the relative toxicity of DMF and its metabolite MMF in vivo remains unclear.

PHARMACOLOGY & THERAPEUTICS (2021)

Article Pharmacology & Pharmacy

Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials

Cinzia Dello Russo, Natalia Cappoli, Daniela Pilunni, Pierluigi Navarra

Summary: In phase 2 oncology trials, local investigators significantly overestimate ORR compared to paired blinded reviewers. This may pose a risk in drug development, especially when deciding whether to move to more expensive phase 3 trials. Blinded independent central review should be used for a more conservative estimate of treatment efficacy.

JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Article Pharmacology & Pharmacy

Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report

Lorenzo Moccia, Pierluigi Lanzotti, Maria Pepe, Laura Palumbo, Delfina Janiri, Giovanni Camardese, Anna Rita Bentivoglio, Marco Di Nicola, Paolo Calabresi, Gabriele Sani

Summary: Functional movement disorders (FMD) are abnormal involuntary movements not consistent with neurological diseases. They often co-occur with mood and anxiety disorders and have poor clinical outcomes. This case report presents the successful treatment of FMD symptoms in a patient with treatment-resistant depression (TRD) using esketamine.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2022)

Review Pharmacology & Pharmacy

Physiological adaptations affecting drug pharmacokinetics in space: what do we really know? A critical review of the literature

Cinzia Dello Russo, Tiziano Bandiera, Monica Monici, Leonardo Surdo, Vincent Lai Ming Yip, Virginia Wotring, Lucia Morbidelli

Summary: As human spaceflight progresses, there is an increasing demand for effective and safe drugs. However, the physiological changes caused by the space environment may alter the pharmacokinetics of drugs. Research on the pharmacokinetics in space is still incomplete, and there is a need to fill the research gaps.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Review Biochemistry & Molecular Biology

Noradrenaline in Alzheimer's Disease: A New Potential Therapeutic Target

Irene L. Gutierrez, Cinzia Dello Russo, Fabiana Novellino, Javier R. Caso, Borja Garcia-Bueno, Juan C. Leza, Jose L. M. Madrigal

Summary: This article summarizes the role of noradrenaline in Alzheimer's disease and suggests the use of noradrenaline-modulating drugs as a therapeutic option.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Pharmacology & Pharmacy

Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature

Cinzia Dello Russo, Pierluigi Navarra

Summary: Several drugs have gained market authorization based on improved progression-free survival as the primary endpoint in Phase 3 clinical trials. An increasing number of drugs have also been approved based on overall response rate evaluation in Phase 1 and 2 trials. However, these outcomes can be influenced by subjective factors, and a blinded independent central review is often adopted to overcome bias.

FRONTIERS IN PHARMACOLOGY (2022)

Review Endocrinology & Metabolism

The biochemical diagnosis of acromegaly: revising the role of measurement of IGF-I and GH after glucose load in 5 questions

Rosa Maria Paragliola, Cinzia Carrozza, Salvatore M. Corsello, Roberto Salvatori

Summary: This article discusses the challenges in measuring growth hormone and insulin-like growth factor I, including biological changes, comorbidities, and assay variability. Interpretation of these measurements is crucial for early diagnosis of acromegaly, avoiding misdiagnosis, and determining if surgery has achieved cure.

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2022)

Review Pharmacology & Pharmacy

LAT1, a novel pharmacological target for the treatment of glioblastoma

Natalia Cappoli, Michael D. Jenkinson, Cinzia Dello Russo, David Dickens

Summary: LAT1 plays a crucial role in glioblastoma development and progression, and its modulation could be a novel therapeutic strategy. LAT1 also plays an important role in the peripheral immune system by regulating the activation status of immune cells. Its function in the reprogramming of the immune component in the glioblastoma tumor microenvironment is still poorly understood.

BIOCHEMICAL PHARMACOLOGY (2022)

Article Clinical Neurology

Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis

Gregorio Spagni, Matteo Gastaldi, Pietro Businaro, Zeineb Chemkhi, Cinzia Carrozza, Giovanni Mascagna, Silvia Falso, Silvia Scaranzin, Diego Franciotta, Amelia Evoli, Valentina Damato

Summary: This study compared the performance of fixed and live cell-based assays in patients with radioimmunoassay-double seronegative myasthenia gravis (dSN-MG). The results showed that the live cell-based assay had a higher ability to detect antibodies in dSN samples. In addition, the live assay was able to detect antibodies that were negative in the fixed assay, further increasing the antibody detection rate.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Article Pharmacology & Pharmacy

Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia

Evelien G. E. Hurkmans, Marije J. Klumpers, Cinzia Dello Russo, Ward De Witte, Henk-Jan Guchelaar, Hans Gelderblom, Anne-Marie Cleton-Jansen, Sita H. Vermeulen, Suzanne Kaal, Winette T. A. van der Graaf, Uta Flucke, Corrie E. M. Gidding, Hendrik W. B. Schreuder, Eveline S. J. M. de Bont, Huib N. Caron, Giovanna Gattuso, Elisabetta Schiavello, Monica Terenziani, Maura Massimino, Geoff McCowage, Sumanth Nagabushan, Anuja Limaye, Victoria Rose, Daniel Catchpoole, Andrea L. Jorgensen, Christopher Barton, Lucy Delaney, Daniel B. Hawcutt, Munir Pirmohamed, Barry Pizer, Marieke J. H. Coenen, D. Maroeska W. M. te Loo

Summary: This study aimed to identify novel genetic variants involved in platinum-induced ototoxicity. A genome-wide association study was conducted in two cohorts, and the results were combined in a meta-analysis. Variants in TSPAN5, RBBP4P5, AC010090.1, and RNU6-38P were suggestively associated with platinum-induced ototoxicity.

FRONTIERS IN PHARMACOLOGY (2023)

Article Genetics & Heredity

A Novel GCK Large Genomic Rearrangement in a Patient withMODY-2 Detected by Clinical Exome Sequencing

Paola Concolino, Linda Tartaglione, Elisa De Paolis, Cinzia Carrozza, Andrea Urbani, Angelo Minucci, Dario Pitocco, Concetta Santonocito

Summary: Maturity-onset diabetes of the young (MODY) is a rare form of non-autoimmune diabetes with an autosomal dominant inheritance. The GCK gene, encoding the glucokinase enzyme, was the first MODY gene to be identified and is responsible for GCK-MODY or MODY2 subtype. However, gene deletions are rarely found in GCK-MODY.

GENES (2022)

Editorial Material Pharmacology & Pharmacy

What is the weight of expectation bias in oncology trials?

Cinzia Dello Russo, Pierluigi Navarra

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Medicine, General & Internal

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

JesseJ Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson, Heshu Abdullah-Koolmees, Kathrin Blagec, Tanja Blagus, Stefan Boehringer, Anne Cambon-Thomsen, Erika Cecchin, Ka-Chun Cheung, Vera H. M. Deneer, Mathilde Dupui, Magnus Ingelman-Sundberg, Siv Jonsson, Candace Joefield-Roka, Katja S. Just, Mats O. Karlsson, Lidija Konta, Rudolf Koopmann, Marjolein Kriek, Thorsten Lehr, Christina Mitropoulou, Emmanuelle Rial-Sebbag, Victoria Rollinson, Rossana Roncato, Matthias Samwald, Elke Schaeffeler, Maria Skokou, Matthias Schwab, Daniela Steinberger, Julia C. Stingl, Roman Tremmel, Richard M. Turner, Mandy H. van Rhenen, Cristina L. Davila Fajardo, Vita Dolzan, George P. Patrinos, Munir Pirmohamed, Gere Sunder-Plassmann, Giuseppe Toffoli, Henk-Jan Guchelaar

Summary: This study assessed the clinical utility of pharmacogenetic testing in patients receiving their first prescription drugs. The results showed that using a pharmacogenetic panel significantly reduced the incidence of clinically relevant adverse drug reactions, and this strategy was feasible across diverse European healthcare system organizations and settings.

LANCET (2023)

Article Biology

REMIFENTANIL DOES NOT AFFECT HUMAN MICROGLIAL IMMUNE ACTIVATION IN RESPONSE TO PRO-INFLAMMATORY CYTOKINES

Cinzia Dello Russo, Natalia Cappoli, Elisabetta Tabolacci, Liliana Sollazzi, Pierluigi Navarra, Paola Aceto

Summary: Remifentanil is a potent analgesic drug used in anesthesia. It may be associated with hyperalgesia, but a study on human microglial cells suggests that it does not have direct immune modulatory actions.

EXCLI JOURNAL (2022)

No Data Available